Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fra…
Biotechnology
US, New York [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Immunovant, Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2024 | -1.8800 | -1.789 | 0 | 0 | -259 | -246 | -269 | 0 | -270 | 0 | 57 | 0 |
| 2025 | - | -2.420 | - | 30 | - | -367 | - | 0 | - | 0 | - | 0 |
| 2026 | - | -2.513 | - | 50 | - | 3.F2X/td> | - | 3.F21/td> | - | 3.F21 | - | 3.F21 |
| 2027 | - | -2.281 | - | 166 | - | 2.F3X/td> | - | 2.F31/td> | - | 2.F31 | - | 2.F31 |
| 2028 | - | -1.190 | - | 387 | - | 1.F4X/td> | - | 1.F41/td> | - | 1.F41 | - | 1.F41 |
| 2029 | - | 1.554 | - | 1,035 | - | 0.F5X/td> | - | 0.F51/td> | - | 0.F51 | - | 0.F51 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-81.424% $21.61 · MISS
Nov. 6, 2024Price Then
$30.32
Price Target
$48.15
Price Now
$26.54